Activity of meropenem/vaborbactam and comparators against Gram-negative isolates from Eastern and Western European patients hospitalized with pneumonia including ventilator-associated pneumonia (2014–19)

OBJECTIVES: Meropenem/vaborbactam has been approved in Europe for the treatment of hospital-acquired bacterial pneumonia, ventilator-associated pneumonia (VAP) and bacteraemia among other indications. Vaborbactam is an inhibitor of class A and C β-lactamases, including Klebsiella pneumoniae carbapen...

Descripción completa

Detalles Bibliográficos
Autores principales: Shortridge, Dee, Carvalhaes, Cecilia, Deshpande, Lalitagauri, Castanheira, Mariana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8446919/
https://www.ncbi.nlm.nih.gov/pubmed/34302173
http://dx.doi.org/10.1093/jac/dkab252

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8446919/
https://www.ncbi.nlm.nih.gov/pubmed/34302173
http://dx.doi.org/10.1093/jac/dkab252

Ejemplares similares